{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:14:02Z","timestamp":1779898442895,"version":"3.53.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.cpcardiol.2022.101345","type":"journal-article","created":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T18:24:26Z","timestamp":1659896666000},"page":"101345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0635-6131","authenticated-orcid":false,"given":"Scott E.","family":"Janus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Heisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Al Jammal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Chahine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Chami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Hajjari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haytham","family":"Mously","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshul","family":"Badhwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpkumar","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Al-Juhaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadeer G.","family":"Al-Kindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Hoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2022.101345_bib0001","article-title":"Acute myeloid leukemia","author":"Vakoto","year":"2022","journal-title":"StatPearls, Treasure Island"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0002","first-page":"747","article-title":"How to treat adult acute myeloid leukemia: an evolving paradigm","volume":"3","author":"Wilson","year":"2021","journal-title":"JACC: Cardio Oncology"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/1559325819887048","article-title":"Targeting approaches of nanomedicines in acute myeloid leukemia","volume":"17","author":"Huang","year":"2019","journal-title":"Dose-Response"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jaccao.2021.11.008","article-title":"Cardiovascular disease among patients with AML and CHIP-related mutations","volume":"4","author":"Calvillo-Arguelles","year":"2022","journal-title":"Jacc CardioOnc"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0005","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/heartjnl-2020-316664","article-title":"Effusive-constrictive pericarditis in the spectrum of pericardial compressive syndromes","volume":"107","author":"Janus","year":"2021","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0006","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/ehjcvp\/pvy035","article-title":"Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System","volume":"5","author":"Serebruany","year":"2019","journal-title":"Euro Heart J - Cardiovasc Pharmacoth"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0007","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.bbmt.2020.08.036","article-title":"Cardiovascular events associated with chimeric antigen receptor T cell therapy: cross-sectional FDA adverse events reporting system analysis: cardiovascular events with CAR-T therapy","volume":"26","author":"Guha","year":"2020","journal-title":"Bio Blood and Marrow Transplant"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2021.663088","article-title":"Pericardial toxicities associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"12","author":"Ma","year":"2021","journal-title":"Frontiers in Pharmacol"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2021.623952","article-title":"Clinical implications of inflammation in acute myeloid leukemia","volume":"11","author":"R\u00e9cher","year":"2021","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0010","first-page":"435","article-title":"Enasidenib: An Oral IDH2 inhibitor for treatment of acute myeloid leukemia","volume":"9","author":"Myers","year":"2018","journal-title":"J Adv Pract Oncology"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0011","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11899-017-0418-6","article-title":"Targeting IDH1 and IDH2 mutations in acute myeloid leukemia","author":"Ragon","year":"2017","journal-title":"Current Hematol Malignancy Reports"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0012","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 analysis of a phase 1\/2 study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0013","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4084\/mjhid.2011.059","article-title":"The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature","volume":"3","author":"Montesinos","year":"2011","journal-title":"Mediterranean J Hematol and Infectious Diseases"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0014","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/cpt.553","article-title":"Targeting BCL2 with BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies","volume":"101","author":"Roberts","year":"2017","journal-title":"Clin Pharmacol and Therap"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0015","first-page":"A11835","article-title":"Abstract 11835: evaluation of cardiovascular adverse events associated with ibrutinib, venetoclax and idelalisib used in treatment of chronic lymphocytic leukemia","volume":"138","author":"Mahida","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0016","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/S0735-1097(00)00647-1","article-title":"Upregulation of the Bcl-2 family of proteins in end stage heart failure","volume":"35","author":"Latif","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0017","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.1995.13.4.983","article-title":"Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia","volume":"13","author":"Tallman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0018","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/15257770.2013.863334","article-title":"Mechanisms of action of fludarabine nucleoside against human raji lymphoma cells","volume":"33","author":"Christopherson","year":"2014","journal-title":"Nucleos, Nucleot and Nucl Acids"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0019","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/bmt.2010.297","article-title":"Large pericardial effusion as a complication in adults undergoing SCT","volume":"46","author":"Norkin","year":"2011","journal-title":"Bone Marr Transplan"},{"key":"10.1016\/j.cpcardiol.2022.101345_bib0020","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1182\/blood-2010-02-246140","article-title":"Beyond hairy cell: The activity of cladribine in other hematologic malignancies","volume":"116","author":"Sigal","year":"2010","journal-title":"Blood"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622002420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622002420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:00:07Z","timestamp":1758938407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280622002420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0146280622002420"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101345","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101345"}}